Bispecific Antibody Deal Benchmarks

Median Upfront

$348M

Range: $194M - $492M

Total Deal Value

$2.2B

Range: $1.4B - $3.0B

Royalty Rate

12.9% - 21.1%

Tiered up to 25.1%

Dev Milestones

$466M

Range: $311M - $623M

Model Your Deal

Market Analysis

Bispecific antibodies represent one of the most actively transacted modalities in oncology licensing. Phase 2 bispecific deals achieve a median total deal value of $2.2B, with upfront payments between $194M and $492M. The modality's versatility across T-cell engagement, dual checkpoint blockade, and receptor crosslinking drives strong licensee interest.

Milestone allocations in bispecific transactions reflect a balanced risk profile. Development milestones average $466M, while regulatory and commercial milestones contribute $745M and $652M, respectively. The overall deal recommendation splits at approximately 16% upfront and 84% milestones.

Royalty rates for bispecific licensing deals range from 12.9% to 21.1% at the base tier, with escalation to 25.1% on high-volume sales. Bispecifics with novel mechanisms (e.g., tumor-conditional activation or half-life extension) tend to attract premium terms relative to conventional T-cell engagers.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the median total deal value for bispecific antibody licensing?

Phase 2 bispecific antibody deals have a median total deal value of $2.2B, ranging from $1.4B to $3.0B depending on mechanism novelty, target validation, and competitive positioning.

How do bispecific deal terms compare to standard monoclonal antibodies?

Bispecific antibody deals typically command a premium over standard monoclonal antibodies due to the dual-mechanism advantage, broader combination potential, and increasing regulatory acceptance. Total deal values for bispecifics are generally 15-30% higher than comparable naked antibody transactions.

What factors influence bispecific antibody deal valuations?

Key valuation drivers include mechanism type (T-cell engagement vs. dual pathway blockade), manufacturing complexity, half-life profile, safety data, and competitive density in the target space. First-in-class bispecifics with differentiated safety profiles command the highest premiums.

What royalty rates are typical for bispecific deals?

Bispecific royalty rates start at 12.9%-21.1% base, escalating to 16.9%-25.1% at the highest sales tier. Rates are influenced by manufacturing cost sharing agreements and co-promotion rights.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Bispecific Antibody Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

ADC Deal Benchmarks

Lung NSCLC Deal Terms

Phase 2 Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?